China
Africa
Explore chapters and articles related to this topic
Bronchitis (Chronic)
Published in Charles Theisler, Adjuvant Medical Care, 2023
Guaifenesin, an expectorant, is used to loosen congestion in the chest and treat cough symptoms by promoting vagally mediated increase in airway secretions.1 Guaifenesin is available over the counter as Mucinex.
Total Intravenous Anesthesia
Published in Michele Barletta, Jane Quandt, Rachel Reed, Equine Anesthesia and Pain Management, 2023
Guaifenesin has been the mainstay for provision of muscle relaxation in equine TIVA protocols for many years. It is a centrally acting muscle relaxant and provides no analgesia. It is available in several concentrations, generally in volumes of 500 ml to 1000 ml.Concentrations greater than 10% should be avoided due to the risk of lysis of red blood cells caused by the high osmolality of the solution.Prolonged infusions or high doses of guaifenesin have been associated with muscle weakness in recovery.
Antihistamines, Decongestants, and Expectorants during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Guaifenesin is a major expectorant in common use, and is an active component of most cough medicines. No animal teratology studies are published. Guaifenesin use during the organogenesis among more than 1,000 human pregnancies was not associated with an increased risk of birth defects (Aselton, 1985; Heinonen et al., 1977; Jick et al., 1981).
Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review
Published in Expert Opinion on Pharmacotherapy, 2022
Maria Gabriella Matera, Barbara Rinaldi, Vito de Novellis, Paola Rogliani, Mario Cazzola
To alleviate the symptoms of ABRS, physicians may prescribe analgesics, intranasal topical corticosteroids, and/or saline nasal irrigations. Due to the findings of randomized controlled trials with various populations, diagnostic criteria, and outcome metrics balancing benefits and harms, the American Academy of Otolaryngology – Head and Neck Surgery Foundation recommended this option [2]. The same guideline discouraged using interventions with questionable or unproven efficacy (antihistamines, systemic steroids), and it deemed it essential to provide information on commonly used interventions (decongestants, guaifenesin) with unknown effects on ABRS symptoms [2].
Dysmenorrhea: A randomized controlled clinical trial evaluating a novel treatment approach
Published in Cogent Medicine, 2018
Hilla Shaviv, Doron J. D. Rosen, Yossef Ezra
Based on the results by Marsden and Strickland (2004) on the effects of guaifenesin (a cervical dilator), we expected a reduction of at least 3 points on the VAS (from a typical value of 6 to 3), with a scatter (variance) of ±3 points. Given that the placebo effect in analgesics is 1 point on VAS, 21 study participants were required to obtain on average a 3σ result above the placebo effect (i.e. at least 99.8% confidence), with an 84% probability of obtaining at least a 2σ result (i.e. at least 97.5% confidence).
Influence of punch geometry (head-flat diameter) and tooling type (‘B’ or ‘D’) on the physical–mechanical properties of formulation tablets
Published in Drug Development and Industrial Pharmacy, 2019
Harsh G. Shah, Rohit P. Dugar, HongHao Li, Vivek S. Dave, Rutesh H. Dave
Prosolv® SMCC 90 HD (silicified microcrystalline cellulose) was obtained from JRS Pharma, Patterson, NY. Guaifenesin was obtained from Letco Pharma, Decatur, AL. Magnesium Stearate was used as a lubricant in the formulations and obtained from Letco Pharma.